title: Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering?
abstract: In spite of extensive investigation, the mechanism for cell cytotoxicity of the anthracycline antitumor drug adriamycin (ADR) has not yet been completely understood but the nature of the cytotoxic effects of this drug is generally related to its interaction with nuclear components, such as DNA and topoisomerase II. In a previous paper, we studied, using Confocal Laser Scanning Microscopy (CLSM), the localization of ADR and its glutathione (GSH)-conjugate (ADRIGLU), obtained by the anaerobic reaction of the parent anthracycline with reduced GSH, in drug-sensitive and in multidrug resistant (MDR) cells. In all drug-sensitive lines used, ADR was mostly located in the nuclei, while its GSH-conjugate was found only in the cytoplasm, predominantly in the Golgi region. In this study we examined the morphological changes induced by ADR or its GSH-conjugated adduct (ADRIGLU) treatments in TVM-A12 (clone 2) melanoma and K562 erythroleukemia human cell lines, correlated to programmed cell death (apoptosis). We observed that ADR-induced apoptosis in both cell lines tested after 5 h treatment: CLSM and Scanning Electron Microscopy (SEM) showed cell shrinkage, fragmentation and condensation of nuclear chromatin, cell surface blebbing and cytoplasmic vacuolization. On the contrary, ADRIGLU-induced fragmentation and condensation of nuclear chromatin, typical of apoptosis, only after 48-72 h treatment. Cytoflourimetric assay by propidium iodide staining confirmed the data obtained by CLSM and SEM. Our data suggest that apoptosis activation by anthracycline antitumor drugs is induced not only by direct interaction with nuclear components but also with cytoplasmic compartments.
authors.affiliation: Institute of Experimental Medicine, Research Area of Rome Tor Vergata, National Research Council, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Serafino
authors.forename: P
authors.initials: P
authors.lastname: Sinibaldi-Vallebona
authors.forename: P
authors.initials: P
authors.lastname: Pierimarchi
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: G
authors.initials: G
authors.lastname: Gaudiano
authors.forename: C
authors.initials: C
authors.lastname: Massa
authors.forename: G
authors.initials: G
authors.lastname: Rasi
authors.forename: G
authors.initials: G
authors.lastname: Ranagnan
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects*; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism*; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000032:analysis; D004317:Doxorubicin / Q000494:pharmacology* / Q000633:toxicity; D005434:Flow Cytometry; D005978:Glutathione / Q000494:pharmacology*; D006801:Humans; D020014:K562 Cells / Q000187:drug effects; D008545:Melanoma / Q000473:pathology; D018613:Microscopy, Confocal; D008856:Microscopy, Fluorescence; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D008929:Mitochondria, Heart / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; C121194:adriamycin-glutathione adduct; D004317:Doxorubicin; D005978:Glutathione